Oxurion NV (OXUR.BR)
EUR 0.27
(0.0%)
EUR 0.27
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 263 Thousand EUR | -55.8% |
| 2022 | 595 Thousand EUR | -47.25% |
| 2021 | 1.12 Million EUR | -45.72% |
| 2020 | 2.07 Million EUR | -47.34% |
| 2019 | 3.94 Million EUR | -25.83% |
| 2018 | 5.32 Million EUR | -8.43% |
| 2017 | 5.81 Million EUR | -18.22% |
| 2016 | 7.1 Million EUR | -36.56% |
| 2015 | 11.19 Million EUR | -18.71% |
| 2014 | 13.77 Million EUR | -87.79% |
| 2013 | 112.78 Million EUR | 50.21% |
| 2012 | 75.08 Million EUR | 2932.43% |
| 2011 | 2.47 Million EUR | -59.9% |
| 2010 | 6.17 Million EUR | 46.57% |
| 2009 | 4.21 Million EUR | -86.15% |
| 2008 | 30.42 Million EUR | 2329.79% |
| 2007 | 1.25 Million EUR | -61.39% |
| 2006 | 3.24 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1000.00 EUR | 0.0% |
| 2023 Q2 | 180 Thousand EUR | 0.0% |
| 2023 Q4 | 83 Thousand EUR | 0.0% |
| 2023 FY | 263 Thousand EUR | -55.8% |
| 2022 FY | 595 Thousand EUR | -47.25% |
| 2022 Q2 | 260 Thousand EUR | 0.0% |
| 2022 Q4 | 335 Thousand EUR | 0.0% |
| 2021 Q2 | 333 Thousand EUR | 0.0% |
| 2021 Q4 | 795 Thousand EUR | 0.0% |
| 2021 FY | 1.12 Million EUR | -45.72% |
| 2020 FY | 2.07 Million EUR | -47.34% |
| 2020 Q4 | 819 Thousand EUR | 0.0% |
| 2020 Q2 | 1.25 Million EUR | 0.0% |
| 2019 Q2 | 1.8 Million EUR | 0.0% |
| 2019 Q4 | 2.13 Million EUR | 0.0% |
| 2019 FY | 3.94 Million EUR | -25.83% |
| 2018 Q2 | 3.75 Million EUR | 0.0% |
| 2018 Q4 | 1.56 Million EUR | 0.0% |
| 2018 FY | 5.32 Million EUR | -8.43% |
| 2017 Q4 | 3.06 Million EUR | 0.0% |
| 2017 FY | 5.81 Million EUR | -18.22% |
| 2017 Q2 | 2.74 Million EUR | 0.0% |
| 2016 Q4 | 3.12 Million EUR | 0.0% |
| 2016 Q2 | 3.98 Million EUR | 0.0% |
| 2016 FY | 7.1 Million EUR | -36.56% |
| 2015 FY | 11.19 Million EUR | -18.71% |
| 2015 Q4 | 5.21 Million EUR | 0.0% |
| 2015 Q2 | 5.98 Million EUR | 0.0% |
| 2014 Q4 | 6.62 Million EUR | 0.0% |
| 2014 Q2 | 7.14 Million EUR | 0.0% |
| 2014 FY | 13.77 Million EUR | -87.79% |
| 2013 Q2 | 102.72 Million EUR | 0.0% |
| 2013 Q4 | 10.05 Million EUR | 0.0% |
| 2013 FY | 112.78 Million EUR | 50.21% |
| 2012 Q1 | 18.77 Million EUR | 0.0% |
| 2012 FY | 75.08 Million EUR | 2932.43% |
| 2012 Q4 | 28.19 Million EUR | 50.21% |
| 2012 Q2 | 18.77 Million EUR | 0.0% |
| 2012 Q3 | 18.77 Million EUR | 0.0% |
| 2011 Q4 | 18.77 Million EUR | 2932.43% |
| 2011 Q1 | 619 Thousand EUR | 0.0% |
| 2011 Q2 | 619 Thousand EUR | 0.0% |
| 2011 FY | 2.47 Million EUR | -59.9% |
| 2011 Q3 | 619 Thousand EUR | 0.0% |
| 2010 FY | 6.17 Million EUR | 46.57% |
| 2010 Q2 | 1.54 Million EUR | 0.0% |
| 2010 Q1 | 1.54 Million EUR | 0.0% |
| 2010 Q3 | 1.54 Million EUR | 0.0% |
| 2010 Q4 | 619 Thousand EUR | -59.9% |
| 2009 Q1 | 1.05 Million EUR | 0.0% |
| 2009 FY | 4.21 Million EUR | -86.15% |
| 2009 Q3 | 1.05 Million EUR | 0.0% |
| 2009 Q2 | 1.05 Million EUR | 0.0% |
| 2009 Q4 | 1.54 Million EUR | 46.57% |
| 2008 Q4 | 1.05 Million EUR | -86.15% |
| 2008 FY | 30.42 Million EUR | 2329.79% |
| 2008 Q1 | 7.6 Million EUR | 0.0% |
| 2008 Q2 | 7.6 Million EUR | 0.0% |
| 2008 Q3 | 7.6 Million EUR | 0.0% |
| 2007 Q3 | 313 Thousand EUR | 0.0% |
| 2007 Q4 | 7.6 Million EUR | 2329.79% |
| 2007 FY | 1.25 Million EUR | -61.39% |
| 2007 Q2 | 313 Thousand EUR | 0.0% |
| 2007 Q1 | 313 Thousand EUR | 0.0% |
| 2006 Q4 | 313 Thousand EUR | -61.39% |
| 2006 FY | 3.24 Million EUR | 0.0% |
| 2006 Q3 | 810.75 Thousand EUR | 0.0% |
| 2006 Q2 | 810.75 Thousand EUR | 0.0% |
| 2006 Q1 | 810.75 Thousand EUR | 0.0% |
| 2005 Q4 | 810.75 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | 94.332% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 94.309% |
| Adocia SA | 2.15 Million EUR | 87.767% |
| Aelis Farma SA | 9.05 Million EUR | 97.095% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | 91.653% |
| genOway Société anonyme | 20.04 Million EUR | 98.688% |
| IntegraGen SA | 12.53 Million EUR | 97.902% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | 12.343% |
| Neovacs S.A. | 533.41 Thousand EUR | 50.695% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | 84.359% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -1228.551% |
| Sensorion SA | 4.74 Million EUR | 94.455% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | 11.248% |
| TME Pharma N.V. | 17 Thousand EUR | -1447.059% |
| Valbiotis SA | 4.73 Million EUR | 94.443% |
| TheraVet SA | 1.07 Million EUR | 75.604% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | 85.389% |
| argenx SE | 1.13 Billion EUR | 99.977% |
| BioSenic S.A. | 543 Thousand EUR | 51.565% |
| Celyad Oncology SA | 102 Thousand EUR | -157.843% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 99.89% |
| Genfit S.A. | 28.56 Million EUR | 99.079% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | 87.398% |
| Innate Pharma S.A. | 51.9 Million EUR | 99.493% |
| Inventiva S.A. | 17.47 Million EUR | 98.495% |
| MaaT Pharma SA | 2.22 Million EUR | 88.196% |
| MedinCell S.A. | 9.16 Million EUR | 97.129% |
| Nanobiotix S.A. | 30.05 Million EUR | 99.125% |
| Onward Medical N.V. | 532 Thousand EUR | 50.564% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 98.147% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 88.19% |
| Pharming Group N.V. | 245.31 Million EUR | 99.893% |
| Poxel S.A. | 1.98 Million EUR | 86.724% |
| GenSight Biologics S.A. | 1.26 Million EUR | 79.242% |
| Transgene SA | 1.18 Million EUR | 77.787% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.995% |
| Valneva SE | 153.71 Million EUR | 99.829% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 107.265% |